BMO Capital Markets reaffirmed their buy rating on shares of AveXis (NASDAQ:AVXS) in a research note released on Monday, January 8th.
Several other research firms also recently commented on AVXS. Royal Bank of Canada began coverage on AveXis in a report on Thursday, September 14th. They issued a sector perform rating and a $92.00 price objective for the company. Wells Fargo & Co reiterated an outperform rating on shares of AveXis in a research report on Friday, September 29th. Citigroup raised their price target on AveXis from $100.00 to $116.00 and gave the stock a buy rating in a research report on Monday, October 2nd. UBS Group reiterated a buy rating and issued a $122.00 target price (up previously from $95.00) on shares of AveXis in a research report on Tuesday, October 3rd. Finally, Goldman Sachs Group reissued a buy rating and set a $130.00 price target on shares of AveXis in a research note on Friday, October 6th. Three analysts have rated the stock with a sell rating, four have issued a hold rating and fourteen have given a buy rating to the company. The stock currently has a consensus rating of Buy and a consensus target price of $113.89.
AveXis (NASDAQ:AVXS) traded down $2.36 during trading on Monday, reaching $122.19. 168,460 shares of the company’s stock were exchanged, compared to its average volume of 766,688. The firm has a market cap of $4,414.96, a P/E ratio of -22.32 and a beta of 2.46. AveXis has a 52 week low of $52.40 and a 52 week high of $128.00.
AveXis (NASDAQ:AVXS) last posted its earnings results on Thursday, November 9th. The company reported ($1.52) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.48) by ($0.04). During the same period last year, the company earned ($0.87) earnings per share. analysts forecast that AveXis will post -6.23 earnings per share for the current year.
In other news, VP Andrew F. Knudten sold 2,000 shares of the stock in a transaction dated Monday, December 4th. The stock was sold at an average price of $94.48, for a total transaction of $188,960.00. Following the transaction, the vice president now directly owns 7,000 shares in the company, valued at approximately $661,360. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, VP Sukumar Nagendran sold 1,780 shares of the firm’s stock in a transaction that occurred on Friday, December 1st. The stock was sold at an average price of $94.77, for a total value of $168,690.60. Following the transaction, the vice president now owns 1,780 shares in the company, valued at $168,690.60. The disclosure for this sale can be found here. Insiders sold a total of 40,560 shares of company stock worth $4,152,752 over the last 90 days. Corporate insiders own 18.60% of the company’s stock.
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in AVXS. Strs Ohio bought a new position in AveXis during the 3rd quarter valued at approximately $116,000. Cubist Systematic Strategies LLC increased its holdings in shares of AveXis by 688.6% in the 3rd quarter. Cubist Systematic Strategies LLC now owns 1,806 shares of the company’s stock worth $175,000 after purchasing an additional 1,577 shares in the last quarter. Teacher Retirement System of Texas bought a new stake in shares of AveXis in the 3rd quarter worth $200,000. Deschutes Portfolio Strategy LLC bought a new stake in shares of AveXis in the 3rd quarter worth $203,000. Finally, Ameritas Investment Partners Inc. increased its holdings in shares of AveXis by 331.0% in the 2nd quarter. Ameritas Investment Partners Inc. now owns 2,112 shares of the company’s stock worth $174,000 after purchasing an additional 1,622 shares in the last quarter. Institutional investors and hedge funds own 82.77% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: “AveXis’ (NASDAQ:AVXS) Buy Rating Reiterated at BMO Capital Markets” was first posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this story on another site, it was illegally stolen and reposted in violation of U.S. & international trademark and copyright laws. The legal version of this story can be read at https://www.dispatchtribunal.com/2018/01/31/avexis-avxs-buy-rating-reiterated-at-bmo-capital-markets.html.
AveXis Company Profile
AveXis, Inc is a clinical-stage gene therapy company. The Company operates through the developing and commercializing gene therapy treatments for patients suffering from neurological genetic diseases segment. The Company’s product candidate, AVXS-101, is its gene therapy product candidate that is in a Phase I clinical trial for the treatment of spinal muscular atrophy (SMA) Type 1, which is a genetic disorder characterized by motor neuron loss and associated muscle deterioration.
Receive News & Ratings for AveXis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AveXis and related companies with MarketBeat.com's FREE daily email newsletter.